Immediate Impact

1 by Nobel laureates 5 from Science/Nature 54 standout
Sub-graph 1 of 24

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout
2 intermediate papers

Works of Clifford DiLea being referenced

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).
2021
Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia
2014

Author Peers

Author Last Decade Papers Cites
Clifford DiLea 138 41 66 118 70 23 431
David J. Sweeny 128 23 50 152 88 30 442
Wayne D. Brenckman 148 30 36 143 49 15 438
Loeckie De Zwart 87 21 50 87 82 23 439
Anjaneya Chimalakonda 103 37 18 112 84 28 434
Nandi J. Reddy 186 17 82 190 66 22 493
Ellen Scheers 73 18 36 135 72 13 396
Vladimir Piotrovsky 165 19 41 196 45 12 462
Kevin Dykstra 90 33 35 93 29 23 511
Kosalaram Goteti 87 28 19 130 59 32 467
S. Bussa 167 6 113 130 56 17 457

All Works

Loading papers...

Rankless by CCL
2026